The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells
This in vitro study investigated whether DMT acts neuroprotective against oxidative stress within cultured neurons and immune cells derived from human precursor cells. Results indicate that DMT robustly increases the survival of these cells in response to severe oxygen deprivation, through activation of the Sig-1 receptor, a key modulator of cellular oxidative stress. The authors postulate that DMT may be endogenously generated to mitigate oxidative stress occasioned by adverse brain injuries such as ischemic infarcts.
Authors
- Jordi Riba
- Attila Szabo
- Ede Ottó Frecska
Published
Abstract
Introduction
N,N-dimethyltryptamine (DMT) is a potent endogenous hallucinogen present in the brain of humans and other mammals. Despite extensive research, its physiological role remains largely unknown. Recently, DMT has been found to activate the sigma-1 receptor (Sig-1R), an intracellular chaperone fulfilling an interface role between the endoplasmic reticulum (ER) and mitochondria. It ensures the correct transmission of ER stress into the nucleus resulting in the enhanced production of antistress and antioxidant proteins. Due to this function, the activation of Sig-1R can mitigate the outcome of hypoxia or oxidative stress.
Methods
In this paper, we aimed to test the hypothesis that DMT plays a neuroprotective role in the brain by activating the Sig-1R. We tested whether DMT can mitigate hypoxic stress in in vitro cultured human cortical neurons (derived from induced pluripotent stem cells, iPSCs), monocyte-derived macrophages (moMACs), and dendritic cells (moDCs).
Results
DMT robustly increases the survival of these cell types in severe hypoxia (0.5% O2) through the Sig-1R. Furthermore, this phenomenon is associated with the decreased expression and function of the alpha subunit of the hypoxia-inducible factor 1 (HIF-1) suggesting that DMT-mediated Sig-1R activation may alleviate hypoxia-induced cellular stress and increase survival in a HIF-1-independent manner.
Discussion
Our results reveal a novel and important role of DMT in human cellular physiology. We postulate that this compound may be endogenously generated in situations of stress, ameliorating the adverse effects of hypoxic/ischemic insult to the brain.
Research Summary of 'The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells'
Introduction
Ahmad and colleagues situate their study within research on the sigma-1 receptor (Sig-1R), an endoplasmic reticulum (ER) chaperone located at mitochondria-associated ER membranes (MAM). Sig-1R has been implicated in regulating Ca2+ signalling, ATP synthesis, ER-to-nucleus stress signalling (via chaperoning proteins such as IRE1), and in modulating cell survival, differentiation and immune responses. Previous in vitro and in vivo work indicates that Sig-1R agonists can protect against hypoxia and ischemic injury, and Sig-1R is expressed across neural and immune tissues. N,N-dimethyltryptamine (DMT), an endogenous tryptamine and known Sig-1R agonist, has been detected in mammalian tissues and is proposed to be sequestered in vesicles and increased by stress, but its physiological role remains unclear. The study therefore tests the hypothesis that DMT confers cellular protection against hypoxic stress via Sig-1R activation. Using human induced pluripotent stem cell (iPSC)-derived cortical neurons and monocyte-derived macrophages and dendritic cells (moMACs and moDCs, considered microglia-like), the investigators examine whether DMT affects survival in severe hypoxia and whether these effects involve modulation of hypoxia-inducible factor 1 alpha (HIF-1α) and dependence on Sig-1R signalling. The work aims to clarify a potential endogenous neuroprotective role for DMT and the mechanistic involvement of Sig-1R in human primary cell models.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., & Frecska, E. (2016). The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells. Frontiers in Neuroscience, 10. https://doi.org/10.3389/fnins.2016.00423
References (7)
Papers cited by this study that are also in Blossom
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Hayashi, T., Vaupel, D. B., Su, T. P. · Science Signaling (2009)
Szabo, A. · Frontiers in Immunology (2015)
Szabo, A., Kovacs, A., Frecska, E. et al. · PLOS ONE (2014)
Cited By (21)
Papers in Blossom that reference this study
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Olson, D. E. · Journal of Neurochemistry (2021)
Show all 21 papersShow fewer
Strumila, R., Guillaume, S. · Pharmaceuticals (2021)
Nichols, C. D., Wiatr, K., Figiel, M. et al. · Journal of Neurochemistry (2021)
Szabó, Í., Varga, V. É., Dvorácskó, S. et al. · Neuropharmacology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Thompson, C., Szabo, A. · Immunology Letters (2020)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)
Barker, S. · Frontiers in Neuroscience (2018)
Cameron, L. P. · ACS Chemical Neuroscience (2018)
Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.